ID: ALA5266735

Max Phase: Preclinical

Molecular Formula: C25H32N6O3

Molecular Weight: 464.57

Representations

Canonical SMILES:  Cc1noc(C)c1-c1nc(-c2cccc(CNC(=O)[C@H](C)N)c2)nc(NC2CCOCC2)c1C

Standard InChI:  InChI=1S/C25H32N6O3/c1-14-22(21-16(3)31-34-17(21)4)29-24(30-23(14)28-20-8-10-33-11-9-20)19-7-5-6-18(12-19)13-27-25(32)15(2)26/h5-7,12,15,20H,8-11,13,26H2,1-4H3,(H,27,32)(H,28,29,30)/t15-/m0/s1

Standard InChI Key:  VHKBFEHAVKFEBK-HNNXBMFYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.57

Molecular Weight (Monoisotopic): 464.2536

AlogP: 3.28

#Rotatable Bonds: 7

Polar Surface Area: 128.19

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.39

CX LogP: 2.48

CX LogD: 1.46

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.49

Np Likeness Score: -1.25

References

1. Zhang Z, Guo Z, Xu X, Cao D, Yang H, Li Y, Shi Q, Du Z, Guo X, Wang X, Chen D, Zhang Y, Chen L, Zhou K, Li J, Geng M, Huang X, Xiong B..  (2021)  Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy.,  64  (22.0): [PMID:34781683] [10.1021/acs.jmedchem.1c01308]

Source

Source(1):

• Scientific Literature